Catalog No.
DHD37502
Description
Lintuzumab is a humanized monoclonal antibody, HuM195, that targets the cell surface antigen CD33 that is expressed on the vast majority of acute myeloid leukemia (AML) cells. [225 Ac]Ac-lintuzumab clinical trials were discussed in detail in reference . Lintuzumab is under investigation in clinical trial NCT00016159 (Chemotherapy Plus Monoclonal Antibody in Treating Patients With Acute Promyelocytic Leukemia).
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Humanized
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Myeloid cell surface antigen CD33, Sialic acid-binding Ig-like lectin 3, Siglec-3, CD33, gp67, SIGLEC3
Concentration
1.39 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P20138
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
225Ac-lintuzumab, HuM195, SGN-33, SMART M195, HuM195, CAS: 166089-32-3
Clone ID
Lintuzumab
Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors, PMID: 29206680
Investigational CD33-targeted therapeutics for acute myeloid leukemia, PMID: 29534618
CD33-Targeted Therapies: Beating the Disease or Beaten to Death?, PMID: 32875599
Targeted Alpha-Particle Therapy for Hematologic Malignancies, PMID: 31253514
Targeted Alpha-Particle Therapy for Hematologic Malignancies, PMID: 32172800
Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia, PMID: 20065652
Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies, PMID: 29793418
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia, PMID: 20858843
5-azacytidine enhances the anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia, PMID: 20495353
225Ac-labeled CD33-targeting antibody reverses resistance to Bcl-2 inhibitor venetoclax in acute myeloid leukemia models, PMID: 33347715
Randomized phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia, PMID: 22801961
Targeted alpha-particle immunotherapy for acute myeloid leukemia, PMID: 24857092
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia, PMID: 15961759
Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial, PMID: 19557623
What happened to anti-CD33 therapy for acute myeloid leukemia?, PMID: 22109628
Newer monoclonal antibodies for hematological malignancies, PMID: 18565392
Novel drugs for older patients with acute myeloid leukemia, PMID: 25142817
Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML, PMID: 28321813
New agents: great expectations not realized, PMID: 24309529
Ab therapy of AML: native anti-CD33 Ab and drug conjugates, PMID: 17917880
Advances in immunotherapy for pediatric acute myeloid leukemia, PMID: 28945115
Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia, PMID: 25762156
Integration of monoclonal antibodies and immunoconjugates into the treatment of acute myeloid leukemia, PMID: 18300754
Antibody therapy for acute myeloid leukemia, PMID: 18381105
ADCs Show Promise in Leukemias, PMID: 27388473
Gateways to clinical trials, PMID: 20094643
Gateways to clinical trials, PMID: 16395422
Gateways to clinical trials, PMID: 12949633
Antibody-dependent cell-mediated cytotoxicity overcomes NK cell resistance in MLL-rearranged leukemia expressing inhibitory KIR ligands but not activating ligands, PMID: 23014531
Precision 're'arming of CD33 antibodies, PMID: 23970353
CD33 splice site genotype was not associated with outcomes of patients receiving the anti-CD33 drug conjugate SGN-CD33A, PMID: 31439003
In Vitro and In Vivo Efficacy of a Novel CD33-Targeted Thorium-227 Conjugate for the Treatment of Acute Myeloid Leukemia, PMID: 27535972
Specific targeting of CD33(+) leukemia cells by a natural killer cell line modified with a chimeric receptor, PMID: 15661266
SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML, PMID: 23770776
Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates, PMID: 14734685
Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia, PMID: 12141950
For research use only. Not for human or drug use.
